I received my PhD degree in Cell and Molecular Biology from Paris-Est University in France in 2014. I accomplished my postdoctoral training at Mayo Clinic in 2020. Since then, I am an Assistant Professor at Mayo Clinic where I study the biology of hepatic stellate cells.

My career goal as an independent physician-scientist investigator in the fields of biomedical engineering, stem cell biology, regenerative medicine, and virology is to build and translate ideas and discoveries in the laboratory to the clinic. My work has involved the development of new stem cell techniques and model systems with the goal to better understand human disease and to develop new clinical treatments. We have an established track record leveraging in vitro and in vivo platforms to model and study human liver disease.

Michael Trauner, MD, received his medical education at the Karl-Franzens-University in Graz, Austria, where he also completed his clinical training in internal medicine and gastroenterology / hepatology. From 1994 to 1997 he postdoctoral research fellow at Yale University's Department of Internal Medicine and Liver Center in New Haven, USA. After returning to Graz, he established an internationally recognized research group in cholestatic and fatty liver diseases, and founded the Liver Center, serving as professor of experimental and clinical hepatology from 2005-2010.

Dr. Schwabe is a Professor of Medicine and the Director of the Digestive and Liver Disease Research Center at Columbia University. His research focuses dissecting the role of hepatic stellate cells in liver homeostasis and MASLD as well as the development of novel therapeutic approaches for liver fibrosis and liver cancer.

Dr. Mavila is an Associate Professor of Medicine and Biomedical Sciences at Cedars-Sinai Medical Center, Los Angeles, CA. Dr. Mavila's research focuses on understanding the molecular mechanisms of liver regeneration during chronic injuries and how dysregulation of these molecular events contributes to the development of liver fibrosis and cancer. We are particularly interested in investigating the cellular crosstalk that occurs during chronic liver injury and its role in the initiation and progression of liver disease.

Pierre-Emmanuel Rautou (MD, PhD) is a clinical specialist in Hepatology with a PhD in vascular biology. He is Professor of Hepatology at Université Paris-Cité and Hôpital Beaujon (Clichy, France) since 2016. He is the head of the Hepatology department at Hôpital Beaujon and is leading an Inserm team dedicated to the study of the role of vessels in liver diseases, at the INSERM Unit 1149 (Paris Research Center on Inflammation).

Theo Heller, M.D. is Chief of the Translational Hepatology Section, Liver Diseases Branch, NIDDK at the NIH. Dr. Heller's scientific interests cover clinical research, including first in human therapeutic studies in hepatitis D, and translational work in humans including factors relating to the progression of liver disease, rare liver diseases such as Portosinusoidal Vascular Disorder, Primary Sclerosing Cholangitis, and Fontan Associated Liver Disease, and the gut-liver axis. He has co-authored over 300 scientific manuscripts.

Margarita German, MD, is a transplant hepatologist and Assistant Professor of Medicine at the University of Wisconsin School of Medicine and Public Health. Her clinical and research interests lie predominantly in optimizing the care of patients with alcohol-associated liver disease (ALD). Dr. German founded a multidisciplinary integrated alcohol-associated liver disease clinic at University of Wisconsin-Madison, where hepatologists, addiction medicine specialists, and a social worker are co-located to provide the most comprehensive care for patients with ALD.

Alyson (Aly) Kaplan is an Assistant Professor of Medicine and Transplant Hepatologist at Tufts University Medical Center's new Abdominal Transplant Institute. Aly is originally from Syosset, New York. She got her BA from Princeton University where she graduated Phi Beta Kappa with a major of psychology. She received her MD from New York University School of Medicine where she was elected alpha omega alpha (AOA).

Nicolas Barros, MD is an Assistant Professor of Clinical Medicine in the Division of Infectious Diseases at the Indiana University School of Medicine and serves as Medical Director of Transplant Infectious Diseases at IU Health University Hospital. He received his medical degree from Universidad Peruana Cayetano Heredia and completed residency training in Internal Medicine and fellowship training in Infectious Diseases at University of Texas Southwestern Medical Center. He subsequently completed advanced training in Transplant Infectious Diseases at Massachusetts General Hospital.